Market Closed -
Nasdaq
16:00:00 2024-05-10 EDT
5-day change
1st Jan Change
15.72
USD
-4.78%
-3.91%
+23.29%
Presentation Operator MessageOperator (Operator)[Audio Gap]
[Oper...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M
05-07
MT
HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating
02-09
MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-08
CI
Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024
02-08
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M
02-08
MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-08
CI
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study
12-12
CI
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
12-05
CI
Truist Starts Curis With Buy Rating
11-17
MT
Transcript : Curis, Inc., Q3 2023 Earnings Call, Nov 02, 2023
11-02
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M
11-02
MT
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-02
CI
India's contaminated cough syrup cases
23-09-13
RE
Transcript : Curis, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Earnings Flash (CRIS) CURIS Reports Q2 Revenue $2.2M, vs. Street Est of $2.5M
23-08-03
MT
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-03
CI
Taseko Mines Provided Financing Update For Florence Copper
23-07-13
MT
HC Wainwright Cuts Price Target on Curis to $6 From $9, Maintains Buy Rating
23-07-07
MT
Sector Update: Health Care Stocks Softer Late Thursday
23-07-06
MT
Sector Update: Health Care Stocks Down Thursday Afternoon
23-07-06
MT
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study
23-07-06
MT
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID
23-07-06
CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
More about the company
Last Close Price
15.72
USD
Average target price
79.8
USD
Spread / Average Target
+407.63%
Consensus
1st Jan change
Capi.
+23.29% 92.66M +17.96% 44.96B +48.77% 41.85B +1.17% 42.65B -4.27% 29.04B +11.42% 26.08B -21.39% 19.03B +4.86% 12.75B +27.29% 12.06B -3.50% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1